Vaccine Delivery: Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8(+) T Cell Responses (Adv. Sci. 1/2018)

Alum, the well‐known vaccine adjuvant with a long history of clinical use, is changed from a “gel” to nanoparticles. This changes its mechanism of action from a “depot” that resides at the injection site, to nanoparticles that transport antigen and adjuvant into the lymph node. As reported by Xun Su...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Hao, Wang, Qin, Li, Lin, Zeng, Qin, Li, Hanmei, Gong, Tao, Zhang, Zhirong, Sun, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Cover Picture
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770673/
http://dx.doi.org/10.1002/advs.201870001
Descripción
Sumario:Alum, the well‐known vaccine adjuvant with a long history of clinical use, is changed from a “gel” to nanoparticles. This changes its mechanism of action from a “depot” that resides at the injection site, to nanoparticles that transport antigen and adjuvant into the lymph node. As reported by Xun Sun and co‐workers in article number 1700426, this lymph node targeting strategy significantly improves the efficacy of vaccinations and offers a potential nanovaccine platform for treating cancer and other diseases. [Image: see text]

Ejemplares similares